LIFECORE BIOMEDICAL, INC. \DE\
LFCRNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $128.9M | $128.3M | $103.3M | $111.3M | $27.8M | $22.7M |
| Operating income | −$17.2M | −$8.8M | −$21.8M | −$11.8M | $73,000 | −$10.6M |
| Net income | −$38.7M | $12.0M | −$99.6M | −$116.7M | −$31.0M | −$12.4M |
| Total assets | $239.3M | $254.0M | $253.5M | $324.2M | $506.9M | $503.0M |
| Total liabilities | $191.9M | $200.1M | $218.5M | $181.7M | $304.7M | $284.5M |
| Equity | $1.3M | $11.3M | −$4.2M | $87.8M | $201.9M | $229.8M |
| EPS (diluted) | $-1.27 | $0.33 | $-3.32 | $-3.97 | $-1.06 | $-0.42 |
| Shares out. | 37.4M | 30.9M | 30.3M | 29.6M | 29.5M | 29.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −13.4%
- Net margin
- −30.0%
- Return on equity
- −2898.0%
- Return on assets
- −16.2%
- Return on capital (ROCE)
- −8.2%
- Liabilities / assets
- 80.2%
- Debt / equity
- 143.64×
- Book value / share
- $0.04
- Revenue growth (YoY)
- 0.5%
- Net income growth (YoY)
- −422.3%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.75distress
- Accruals / assets
- −16.1%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Aug 12, 2024
- NT 10-Qmissed a reporting deadline ↗Apr 8, 2024
- NT 10-Qmissed a reporting deadline ↗Jan 10, 2024
- NT 10-Qmissed a reporting deadline ↗Oct 10, 2023
- NT 10-Kmissed a reporting deadline ↗Aug 14, 2023
- NT 10-Qmissed a reporting deadline ↗Apr 10, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Blackrock, Inc.Passive (13G)Apr 27, 2026
- 22nw Fund, LpActivist (13D)May 29, 2025
- Greenhaven Road Investment Management, L.P.Passive (13G)Feb 14, 2025
- David Capital Partners, LlcPassive (13G)Feb 5, 2025
- Lw Capital Management, LlcPassive (13G)Feb 14, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.6M | 13.4 | -5.1% |
| Apr 30, 2026 | 2.7M | 12.0 | +1.8% |
| Apr 15, 2026 | 2.7M | 6.2 | +2.3% |
| Mar 31, 2026 | 2.6M | 3.4 | +0.6% |
| Mar 13, 2026 | 2.6M | 17.2 | -5.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 6, 2026
- Results of operations · Regulation FD disclosureMar 16, 2026
- Item 5.08Mar 5, 2026
- Director / officer changeJan 16, 2026
- Regulation FD disclosureNov 17, 2025
- Results of operations · Regulation FD disclosureNov 6, 2025
- Shareholder voteOct 31, 2025
- Director / officer changeSep 26, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.